Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. **(Currently Amended)** ~~**An entity selected from: a**~~ **A** compound of Formula (I) :



(I)

and a physiologically functional derivative thereof,

wherein:

R^1 is selected from: hydrogen and C_{1-4} alkyl which **is optionally** ~~**may be optionally**~~ substituted with one or more groups selected from CN and CF_3;
R^2 is selected from: C_{3-10} unsubstituted alkyl, C_{1-10} alkyl substituted with one or more groups selected from fluorine and CN, C_5 alkenyl, unbranched C_4 alkenyl, and C_{1-4} alkyl substituted with cycloalkyl; and
R^3 is selected from halogen and CN;

~~**with the**~~ provided ~~**proviso**~~ that:

(i) when R^3 represents Cl, and R^1 represents ethyl, R^2 is other than propyl;

(ii) when R^3 represents Br, and R^1 represents propyl, R^2 is other than propyl;

(iii) when R^3 represents Cl or Br, and R^1 represents butyl, R^2 is other than butyl; and

(iv) when R^1 represents C_{1-4} alkyl, CH_2CN, or $(CH_2)_3CF_3$, R^2 is other than branched alkyl.

2. **(Currently Amended)** A compound according to claim 1, wherein:
R^1 is selected from: hydrogen, C_{1-4} alkyl, CH_2CN and $(CH_2)_3CF_3$;
R^2 is selected from: C_{3-10} unsubstituted alkyl, $(CH_2)_{1-5}CN$, C_{2-5} alkyl with one or more fluorine substitutions, C_5 alkenyl and C_{1-4} alkyl substituted with cycloalkyl; and

R^3 is selected from halogen and CN;

~~with the~~ provided ~~proviso~~ that:
(i) when R^3 represents Cl, and R^1 represents ethyl, R^2 is other than propyl;
(ii) when R^3 represents Cl or Br and R^1 represents butyl, R^2 is other than butyl; and
(iii) when R^1 represents C_{1-4} alkyl, CH_2CN, or $(CH_2)_3CF_3$, R^2 is other than branched alkyl.

3. **(Currently Amended)** A compound according to claim 1, ~~or 2~~ wherein R^1 is selected from: hydrogen and methyl.

4. **(Currently Amended)** A compound according to **claim 1,** ~~any preceding claim~~ wherein R^2 is selected from: C_{4-6} unsubstituted n-alkyl, $(CH_2)_{1-3}CN$, C_{3-4} alkyl with one or more fluorine substitutions and C_5 alkenyl.

5. **(Currently Amended)** A compound according to **claim 1,** ~~any preceding claim~~ wherein R^3 ~~represents~~ **is** halogen.

6. **(Currently Amended)** A compound according to **claim 1,** ~~any preceding claim~~ wherein R^3 is selected from: ~~chlorine~~ and bromine.

7. **(Currently Amended)** A compound according to **claim 1,** ~~any preceding claim~~ wherein R^3 ~~represents~~ **is** chlorine.

8. **(Cancelled).**

9. **(Cancelled).**

10. **(Currently Amended)** A method for ~~compound according to claim 1 any one of claims 1-7, for use in the~~ treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular ~~disease~~ **diseases, disorders of lipid metabolism,** ~~including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia,~~ type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke, **comprising administration of a compound of Formula (I) according to claim 1.**

11. **(Currently Amended)** ~~**An entity selected from: a**~~ **A** compound of Formula (II) :



(II)

and a physiologically functional derivative thereof,

wherein:

R^1 is selected from: hydrogen and C_{1-4} alkyl which may be optionally substituted with one or more groups selected from CN and CF_3;
R^2 is selected from: C_{2-10} unsubstituted alkyl, C_{1-10} alkyl substituted with one or more groups selected from fluorine and CN, C_5 alkenyl, unbranched C_4 alkenyl, and C_{1-4} alkyl substituted with cycloalkyl; and R^3 is selected from halogen and CN.
~~**for use in the manufacture of a medicament for treating diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridaemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure or stroke.**~~

12. **(Currently Amended)** A method for ~~**the**~~ treatment of a human or animal subject having a condition where under-activation of ~~**the**~~ HM74A receptor contributes to the condition or where activation of the **HM74A** receptor will be beneficial, which ~~**method**~~ comprises administering to said human or animal subject an effective amount of ~~**an entity selected from:**~~ a compound of Formula (II)



(II)

and a physiologically functional derivative thereof,

wherein:

R^1 is selected from: hydrogen and C_{1-4} alkyl which **is** ~~**may be**~~ optionally substituted with one or more groups selected from CN and CF_3;

R^2 is selected from: C_{2-10} unsubstituted alkyl, C_{1-10} alkyl substituted with one or more groups selected from fluorine and CN, C_5 alkenyl, unbranched C_4 alkenyl, and C_{1-4} alkyl substituted with cycloalkyl; and R^3 is selected from halogen and CN.

13. (**Currently Amended**) A method according to claim 12, wherein the human or animal subject has a disorder of lipid metabolism **selected from** ~~**including**~~ dyslipidaemia, **or** hyperlipoproteinaemia or an inflammatory disease or condition.

14. (**Currently Amended**) A pharmaceutical formulation comprising a compound according to **claim 1** ~~**any one of claims 1-7,**~~ and one or more physiologically acceptable diluents, excipients or carriers.

15. (**Currently Amended**) A combination for administration together or separately, sequentially or simultaneously in separate or combined pharmaceutical formulations, said combination comprising a compound according to **claim 1,** ~~**any one of claims 1-7,**~~ together with another therapeutically active agent.

16. (**Currently Amended**) A pharmaceutical formulation comprising:
    (i) a compound according to **claim 1** ~~**any one of claims 1-7;**~~
    (ii) one or more active ingredients selected from statins, fibrates, bile-acid binding resins ~~**and**~~ or nicotinic acid; and
    (iii) one or more physiologically acceptable diluents, excipients or carriers.

17. (**Currently Amended**) A method for ~~**the**~~ preparation of a compound according to **claim 1,** ~~**any one of claims 1-7,**~~ in which R^3 is halogen, **wherein** the method ~~**comprising**~~ **comprises steps of:**
    (i) alkylation at N1 or N3, or dialkylation at N1 and N3 of an N7 protected xanthine;
    (ii) halogenation at C8; and
    (iii) de-protection;
    wherein steps (i), (ii) or (iii) are in any order providing de-protection is carried out after alkylation~~.~~ **at N1 or N3 as defined in step (i).**

18. (**New**) A method according to claim 10, wherein cardiovascular diseases are selected from atherosclerosis, arteriosclerosis, and hypertriglyceridaemia.

19. **(New)** A method according to claim 10, wherein disorders of lipid metabolism are selected from dyslipidaemia, hyperlipoproteinaemia or inflammatory diseases or conditions.

20. **(New)** A method for treatment of diabetic dyslipidaemia, mixed dyslipidaemia, heart failure, hypercholesteraemia, cardiovascular diseases, disorders of lipid metabolism type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidaemia, anorexia nervosa, obesity, coronary artery disease, thrombosis, angina, chronic renal failure, peripheral vascular disease or stroke, comprising administration of a compound of Formula (II) according to claim 11.